Immunogenicity and Safety of an Inactivated Quadrivalent Influenza Vaccine Candidate: A Phase III Randomized Controlled Trial in Children

Background. Mismatch between circulating influenza B viruses (Yamagata and Victoria lineages) and vaccine strains occurs frequently. Methods. In a randomized controlled trial, immunogenicity and safety of an inactivated quadrivalent influenza vaccine candidate (QIV) versus trivalent inactivated influenza vaccine (TIV)-Victoria(Vic) and TIV-Yamagata(Yam) in children 3–17 years of age was evaluated. In an open-label study arm, QIV only was assessed in children 6–35 months of age. Results. A total of 3094 children (932 QIV, 929 TIV-Vic, 932 TIV-Yam, and 301 QIV only) were vaccinated. QIV was noninferior to the TIVs for shared strains (A/H3N2 and A/H1N1) based on hemagglutination-inhibition (HI) antibodies 28 days after last vaccination, and superior for the unique B strains Victoria and Yamagata (geometric mean titer ratios 2.61, 3.78; seroconversion rate differences 33.96%, 44.63%). Among children in the randomized trial, adverse event rates were similar except for injection site pain (dose 1: 65.4% QIV, 54.6% TIV-Vic, 55.7% TIV-Yam). Conclusion. QIV elicited superior HI responses to the added B strains compared to TIV controls, potentially improving its effectiveness against influenza B. HI responses were similar between QIV and TIV controls for the shared strains. QIV had an acceptable safety profile relative to TIVs. Clinical Trials Registration. NCT01198756.

[1]  Sarah Cobey,et al.  Improving influenza vaccine virus selection: report of a WHO informal consultation held at WHO headquarters, Geneva, Switzerland, 14–16 June 2010 , 2013, Influenza and other respiratory viruses.

[2]  R. Holman,et al.  Myocardial injury and bacterial pneumonia contribute to the pathogenesis of fatal influenza B virus infection. , 2012, The Journal of infectious diseases.

[3]  C. Reed,et al.  Public health impact of including two lineages of influenza B in a quadrivalent seasonal influenza vaccine. , 2012, Vaccine.

[4]  O. Vanderkooi,et al.  Immunogenicity and Safety of 2 Dose Levels of a Thimerosal-Free Trivalent Seasonal Influenza Vaccine in Children Aged 6–35 Months: A Randomized, Controlled Trial , 2012, Journal of the Pediatric Infectious Diseases Society.

[5]  D. Skowronski,et al.  Antibody persistence and response to 2010-2011 trivalent influenza vaccine one year after a single dose of 2009 AS03-adjuvanted pandemic H1N1 vaccine in children. , 2011, Vaccine.

[6]  D. Skowronski,et al.  Influenza B/Victoria Antigen Induces Strong Recall of B/Yamagata But Lower B/Victoria Response in Children Primed With Two Doses of B/Yamagata , 2011, The Pediatric infectious disease journal.

[7]  N. Ferguson,et al.  Improving influenza vaccine virus selectionReport of a WHO informal consultation held at WHO headquarters, Geneva, Switzerland, 14–16 June 2010 , 2011, Influenza and other respiratory viruses.

[8]  D. Skowronski,et al.  Randomized Controlled Trial of Dose Response to Influenza Vaccine in Children Aged 6 to 23 Months , 2011, Pediatrics.

[9]  C. Giaquinto,et al.  Clinical manifestations and socio-economic impact of influenza among healthy children in the community. , 2011, The Journal of infection.

[10]  R. Belshe.  The need for quadrivalent vaccine against seasonal influenza. , 2010, Vaccine.

[11]  R. Belshe,et al.  Efficacy of live attenuated influenza vaccine in children against influenza B viruses by lineage and antigenic similarity. , 2010, Vaccine.

[12]  N. Cox,et al.  Prevention and control of seasonal influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2009. , 2009 .

[13]  C. V. Hoecke,et al.  Ten Years of Experience with the Trivalent Split-Influenza Vaccine, Fluarix™ , 2002 .

[14]  R. Sorelle.  US Department of Health and Human Services gives states wider latitude in choosing services to be covered by Medicaid. , 2001, Circulation.

[15]  A. Kendal,et al.  Cocirculation of two distinct evolutionary lineages of influenza type B virus since 1983. , 1990, Virology.

[16]  C. Bridges,et al.  17 – Inactivated influenza vaccines , 2013 .

[17]  Recommended composition of influenza virus vaccines for use in the 2013 southern hemisphere influenza season. , 2012, Releve epidemiologique hebdomadaire.

[18]  D. Maki,et al.  Influenza-associated pediatric deaths--United States, September 2010-August 2011. , 2011, MMWR. Morbidity and mortality weekly report.

[19]  J. Kaldor,et al.  Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2010. , 2010, MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports.

[20]  N. Cox,et al.  Prevention and Control of Influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP). , 2006, MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports.

[21]  W. Roper,et al.  Prevention and control of influenza: Part I, Vaccines. Recommendations of the Advisory Committee on Immunization Practices (ACIP). , 1994, MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports.

[22]  R. Couch,et al.  Epidemiologic observations of influenza B virus infections in Houston, Texas, 1976-1977. , 1980, American journal of epidemiology.

[23]  T. A. Bektemirov,et al.  [Inactivated influenza vaccines]. , 1978, Voprosy virusologii.